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Abstract
The p53 transcription factor and tumor suppressor is regulated primarily by the E3 ubiquitin ligase Mdm2, which
ubiquitinates p53 to target it for proteasomal degradation. Aside from its ubiquitin ligase function, Mdm2 has been
believed to be capable of suppressing p53’s transcriptional activity by binding with and masking the transactivation domain
of p53. The ability of Mdm2 to restrain p53 activity by binding alone, without ubiquitination, was challenged by a 2007
study using a knockin mouse harboring a single cysteine-to-alanine point mutation (C462A) in Mdm2’s RING domain. Mouse
embryonic fibroblasts with this mutation, which abrogates Mdm2’s E3 ubiquitin ligase activity without affecting its ability to
bind with p53, were unable to suppress p53 activity. In this study, we utilized the Mdm2
C462A mouse model to characterize
in further detail the role of Mdm2’s RING domain in the control of p53. Here, we show in vivo that the Mdm2
C462A protein
not only fails to suppress p53, but compared to the complete absence of Mdm2, Mdm2
C462A actually enhances p53
transcriptional activity toward p53 target genes p21/CDKN1A, MDM2, BAX, NOXA, and 14-3-3s. In addition, we found that
Mdm2
C462A facilitates the interaction between p53 and the acetyltransferase CBP/p300, and it fails to heterodimerize with its
homolog and sister regulator of p53, Mdmx, suggesting that a fully intact RING domain is required for Mdm2’s inhibition of
the p300-p53 interaction and for its interaction with Mdmx. These findings help us to better understand the complex
regulation of the Mdm2-p53 pathway and have important implications for chemotherapeutic agents targeting Mdm2, as
they suggest that inhibition of Mdm2’s E3 ubiquitin ligase activity may be sufficient for increasing p53 activity in vivo,
without the need to block Mdm2-p53 binding.
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Introduction
The p53 tumor suppressor protein is frequently mutated in
cancer, with approximately 50% of cancers containing mutations
that inactivate p53 itself, and many of the remaining cancers
thought to harbor mutations that otherwise inactivate the p53
tumor suppressor pathway [1]. In response to DNA damage and
other stimuli, p53 induces cell cycle arrest or apoptosis by
transcriptionally activating genes that control these processes. In
healthy cells, it is essential that p53’s activity be kept in check so
that the normal cell cycle can proceed. This control of p53 is
accomplished primarily by the E3 ubiquitin ligase Mdm2 (murine
double minute 2) [2].
Mdm2 has long been thought to inactivate p53 in two ways: by
ubiquitinating p53 to induce its degradation, and by binding with
p53 to conceal its transactivation domain. Mdm2 serves as an E3
ubiquitin ligase that conjugates a chain of ubiquitin molecules onto
p53, targeting p53 for proteasome-mediated degradation [3,4,5].
In addition, Mdm2 binds with a region of p53 that overlaps with
its transactivation domain, and many in vitro and/or overexpres-
sion studies supported the idea that Mdm2 binding alone, without
ubiquitination, could suppress p53’s transactivational activity
[6,7,8].
A recent study by Itahana et al. [9] using an Mdm2 knockin
mouse challenged the notion that Mdm2 is capable of suppressing
p53 activity through binding alone. In that study, a knockin mouse
was generated in which a single cysteine-to-alanine point mutation
(C462A) was introduced into Mdm2’s RING domain in order to
abrogate Mdm2’s E3 ubiquitin ligase activity without affecting the
protein’s ability to bind with p53 [10,11]. Using this mouse model,
designated as Mdm2
C462A/C462A (hereafter referred to as Mdm2
m/m),
the separate contributions of Mdm2’s E3 ubiquitin ligase activity
and its ability to bind with p53 could be analyzed in vivo under
conditions of endogenous protein expression. Using mouse
embryonic fibroblast (MEF) cells obtained from this model,
Itahana et al. showed that the Mdm2
C462A protein was capable
of binding with p53 yet could not ubiquitinate p53 nor elicit its
degradation [9].
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without ubiquitination, is not capable of inhibiting p53’s activity,
two issues became apparent: first, the expression of only one p53
target, aside from Mdm2 itself, was examined, and second, it was
not shown that the mutant Mdm2 retained the ability to interact
with p53 while on a target gene promoter. The study here aimed
to address these concerns and further characterize the contribution
of Mdm2’s RING domain in suppressing p53. We show that
Mdm2
C462A indeed interacts with p53 on the p21 promoter and
that Mdm2
C462A fails to suppress transcription of multiple p53
targets, including p21, Mdm2, Bax, Noxa, and 14-3-3s.
Interestingly, we found that Mdm2-p53 binding alone, without
ubiquitination, not only fails to inhibit p53, but actually further
enhances p53 activity toward each of these targets compared to
the complete absence of Mdm2. Finally, we show that binding of
Mdm2
C462A to p53 enhances the interaction between p53 and the
acetyltransferase CBP/p300, suggesting a mechanism for the
enhanced p53 activity.
Results
Mdm2
C462A enhances p53 transcriptional activity
First, we examined the effect of Mdm2
C462A on p53’s
transcriptional activity in vivo using MEF cells. Mice harboring
the Mdm2
C462A mutation are not viable due to unchecked p53
activity [9]. To avoid this complication, the mice were intercrossed
with mice harboring an inducible p53 (p53
ER), in which p53 is
fused with a portion of the estrogen receptor protein, rendering it
inactive until treatment with the estrogen mimic, 4-hydroxyta-
moxifen (4-OHT) [12]. Mdm2
m/m; p53
ER/2 mice are viable, and
MEF cells from these mice can be used for studies requiring both
mutant Mdm2 and active p53, as 4-OHT can be added to
cultured MEF cells to induce p53 activation. To assess the effect of
the C462A mutation on p53 activity, MEF cells from Mdm2
+/+;
p53
ER/2, Mdm2
2/2; p53
ER/2, and Mdm2
m/m;p53
ER/2 mice were
treated with 4-OHT to reactivate p53 and were lysed after zero,
12, or 24 hours. RNA was isolated from each sample and
subjected to RT-PCR to assess transcription of the p53 targets
Mdm2, p21, Bax, Noxa, and 14-3-3s. Transcription of these
genes was elevated in the mutant MEFs compared to wild-type
cells, confirming Itahana et al.’s finding that the RING C462A
mutation renders Mdm2 unable to suppress p53 activity.
Surprisingly, however, these p53 targets were expressed to a
greater extent in MEFs expressing Mdm2
C462A than in Mdm2-null
cells. Transcription was elevated in Mdm2
m/m MEFs compared to
Mdm2
+/+ and Mdm2
2/2 MEFs at both the 12-hour and 24-hour
time points for the five p53 targets examined (Fig. 1A), indicating
that the ubiquitination-deficient Mdm2
C462A protein not only fails
to inhibit p53’s transcriptional activity, but enhances it compared
to lack of Mdm2.
To determine whether the increase in transcription correlated
with increased expression of protein, levels of p21 were assessed by
western blotting. MEF cells treated as described above were lysed
with 0.5% NP-40 lysis buffer and resolved by SDS PAGE. Relative
levels of p53, Mdm2, and the p53 target p21 were assessed by
western blotting. The p21 protein level was elevated in Mdm2
m/m;
p53
ER/2 MEFs compared to Mdm2
+/+;p53
ER/2 MEFs and
Mdm2
2/2;p53
ER/2 MEFs (Fig. 1B). It should be noted that the
reduced p53 level in Mdm2
+/+;p53
ER/2 MEFs is due to the Mdm2-
p53 negative feedback loop; activation of p53 by administration of
4-OHT leads to enhanced transcription of Mdm2, which in turn
targets p53 for degradation. This Mdm2-mediated degradation of
p53 is absent in both Mdm2-null MEFs and those with the C462A
mutation, which renders Mdm2 incapable of degrading p53.
Together, these data show that the Mdm2 C462A RING
domain mutation results in increased p53 transcriptional activity,
suggesting that Mdm2-p53 binding alone, without ubiquitination
of p53, not only fails to suppress p53, but leads to enhanced p53
activity.
Mdm2
C462A facilitates binding between p53 and CBP/
p300
We explored potential mechanisms for the increased p53
activity observed in cells with the Mdm2 C462A mutation. Mdm2
has been thought to inhibit p53’s transcriptional activity by
interacting with p53 on its target gene promoters and masking the
transactivation domain of p53. As shown above, Mdm2
C462A
retains its ability to interact with p53, yet does not suppress p53
activity [9]. However, it is possible that the mutant Mdm2 may not
interact with p53 while located on p53’s target gene promoters and
is unable to control p53 activity due to this defect. To rule out this
possibility, it is essential to determine whether the Mdm2
C462A-p53
interaction can take place on the promoter of a p53 target gene.
To address this directly, chromatin immunoprecipitation (ChIP)
analysis was carried out to assess p53-Mdm2 binding on the p21
promoter in Mdm2
m/m;p53
ER/2 MEFs cells. Mdm2
m/m;p53
2/2 cells
were included as a negative control. The cells were incubated with
4-OHT for 24 hours to activate p53, and formaldehyde was
applied to crosslink proteins to DNA. The cells were lysed,
sonicated to shear DNA, and immunoprecipitated with p53
antibody or IgG (negative control). A subset of each sample was
resolved by SDS PAGE and western blotting, while another
portion was subject to reverse crosslinking and PCR targeting the
p21 (CDKN1A) promoter (Fig. 2A). PCR product indicating
presence of the p21 promoter was detected equally in all three
input samples, but following immunoprecipitation with p53
antibody, was present only in the sample from Mdm2
m/m;p53
ER/2
MEFs. DNA from the p21 promoter was not detected in Mdm2
m/m;
p53
ER/2 MEFs immunoprecipitated with IgG or in p53-null MEFs
immunoprecipitated with p53 antibody (negative controls)
(Fig. 2B). Western blotting of the samples showed that both
Mdm2 and p53 were present in Mdm2
m/m;p53
ER/2 MEFs
immunoprecipitated with p53 antibody. No Mdm2 or p53 was
detected in control samples immunoprecipitated with IgG alone or
from p53-null MEFs (Fig. 2C). These data indicate that
Mdm2
C462A interacts with p53 on the p21 gene promoter.
We next considered potential mechanisms for the paradoxical
observation that p53 activity was enhanced in the Mdm2
m/m MEFs
compared to Mdm2-null MEFs. p53 activity can be dramatically
increased by acetylation, and p53 is well-known to be acetylated
by its transcription cofactor, the acetyltransferase CBP/p300
[13,14]. In response to p53-activating stressors, p300 acetylates
lysine residues in p53’s DNA binding domain, strongly stimulating
p53’s sequence-specific interaction with DNA [13,14,15,16,17,18].
As examination of acetylation of endogenous p53 in MEF cells
presents a technical challenge, we determined instead whether the
C462A mutation could affect the interaction between p53 and
p300. MEF cells of the genotypes Mdm2
+/+;p53
ER/2, Mdm2
m/m;
p53
ER/2, and Mdm2
m/m;p53
2/2 were lysed with 0.1% NP-40 lysis
buffer, immunoprecipitated with p53 antibody, resolved by SDS-
PAGE, and blotted for p300 and p53. The presence of the C462A
mutation greatly enhanced the interaction between p53 and p300,
as evidenced by a stronger band representing p300 after
immunoprecipitating p53-containing complexes in the Mdm2
m/m;
p53
ER/2 MEFs compared to the Mdm2
+/+;p53
ER/2 MEFs. No
p300 was immunoprecipitated in the p53-null negative control
sample (Fig. 3). This result indicates that Mdm2
C462A promotes
p300-p53 binding. Because p300 is well-known to activate p53
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interaction is associated with enhanced acetylation [19], the effect
of the C462A mutation on p300-p53 binding provides an
explanation for the excess p53 activity observed in Mdm2
m/m
MEFs compared to Mdm2-null MEFs.
Discussion
This work provides further evidence that Mdm2 harboring a
point mutation that abrogates its E3 ubiquitin ligase activity
without affecting Mdm2-p53 binding is not capable of suppressing
p53 activity. We show that Mdm2
C462A fails to repress transcrip-
tion of five target genes, yet retains its ability to interact with p53
on the promoter of its target gene p21/CDKN1A. These data,
complementing the 2007 study by Itahana et al. [9], challenge the
long-held belief that Mdm2 can suppress p53 activity merely by
binding to p53 and masking its transactivation domain. We show,
along with the aforementioned study, that an intact E3 ubiquitin
ligase activity is necessary for Mdm2 to inhibit p53 in vivo under
conditions of endogenous protein expression. These findings have
implications for the development of pharmaceuticals targeting
Mdm2, demonstrating that it is not necessary to disrupt Mdm2-
p53 binding in order to release p53 activity.
Our data show that Mdm2
C462A not only fails to suppress p53
activity, but, surprisingly, the mutant protein yields greater p53
activation than does the complete absence of Mdm2. This study
also uncovered a potential mechanism for the increased p53
activity, showing that the C462A mutation facilitates binding
between p53 and the acetyltransferase CBP/p300. The p300-
mediated acetylation of p53 has been well-established to activate
p53 in vivo [13,15,16,17]. Interestingly, wild-type Mdm2 is known
to inhibit p300-mediated acetylation of p53 through formation of
an Mdm2-p53-p300 ternary complex [18,20,21], whereas our
data show that a single point mutation in Mdm2’s RING domain
conveys an opposing effect, leading to enhancement of the p53-
p300 interaction and increased p53 activity. This implies that an
intact RING domain may be necessary for Mdm2’s inhibition of
p300-mediated acetylation of p53.
How might disruption of Mdm2’s RING domain enhance the
p53-p300 interaction? Is it due to lack of E3 ubiquitin ligase
activity, or is it caused by another essential function of the RING
domain? E3 ubiquitin ligase activity is not likely to be essential for
Figure 1. A) Quantitative real-time PCR analysis of p53 target genes in MEF cells pre-treated with 4-OHT for 24 hours to activate
p53
ER. Values represent an average of three samples measured relative to GAPDH, and error bars indicated standard deviation. All samples are of the
genotype p53
ER/2 with Mdm2 status as indicated below graph. B) Western blot analysis of p21 expression in MEF cells of indicated genotypes at 0, 12,
and 24 hours following treatment with 4-OHT to activate p53
ER. Actin is shown as loading control.
doi:10.1371/journal.pone.0038212.g001
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lacks E3 ligase activity yet has been shown to inhibit p300-
mediated acetylation of p53. It is possible that another function of
the RING domain influences the interaction. One hypothesis is
that formation of an Mdm2-Mdmx heterodimer may be necessary
for Mdm2 to inhibit p300, as the RING domain was shown to
mediate this heterodimerization [22], and Mdmx inhibits p300-
mediated acetylation of p53 [23]. That is, the heterodimer may be
more efficient at inhibiting p300-p53 binding than Mdm2 or
Mdmx alone. To determine whether the RING point mutation
affects Mdm2-Mdmx binding in vivo, we carried out a co-
immunoprecipitation (co-IP) for Mdm2 in Mdm2
+/+;p53
ER/2 and
Mdm2
m/m;p53
ER/2 MEF cells. We found that the C462A RING
mutation disrupts the interaction between Mdm2 and Mdmx
(Fig. 4), indicating that an intact RING domain is necessary for
Mdm2-Mdmx heterodimerization in vivo. Thus, it is possible that
the enhanced p53 activity and p300-p53 interaction produced by
Mdm2
C462A may stem from its inability to heterodimerize with
Mdmx. We present a hypothesized model in which the Mdm2-
Mdmx heterodimer inhibits p300-p53 binding in vivo, while
monomeric Mdm2 promotes this interaction. In this model,
heterodimerization between Mdm2 and Mdmx blocks p300-p53
binding and p300-mediated acetylation of p53. In Mdm2-null
cells, this inhibition is released, permitting p300 to interact with
and acetylate p53. When Mdm2 exists as a monomer rather than a
heterodimer, as is the case, presumably, with Mdm2
C462A, (if not
able to dimerize with Mdmx, it is also not likely to dimerize with
itself), not only is it unable to inhibit p300-mediated acetylation of
p53, but the monomeric Mdm2 further enhances this acetylation
beyond the basal level found in Mdm2-null cells. This may be a
result of monomeric Mdm2 bridging together p300 and p53, as
Mdm2 is known to interact with both of these proteins [20,21]. We
speculate that the Mdm2-Mdmx heterodimer is not able to
promote p300-p53 binding, perhaps due to bulkiness or another
inherent difference between the monomer and the heterodimer
(Fig. 5). It should be noted that this study does not specifically
differentiate between Mdm2-Mdmx heterodimerization and
Mdm2-Mdm2 homodimerization. Ultimately, further research
will be needed to determine whether the effect of Mdm2
C462A on
the p300-p53 interaction is mediated by its ability to hetero-
dimerize with Mdmx, or by another mechanism.
Nonetheless, these data show that Mdm2-p53 binding alone is
not sufficient for inhibiting p53 activity or p53’s interaction with
the acetyltransferase p300, enhancing our understanding of the
complex regulation of the p53 tumor suppressor pathway.
Materials and Methods
Mouse Generation and Maintenance
Mice were generated, maintained, and genotyped as described
previously [9].
Figure 2. A) Schematic depicting chromatin immunoprecipitation (ChIP) analysis carried out to assess Mdm2-p53 binding on the
promoter of the p53 target, p21. MEF cells were pre-treated with 4-OHT for 24 hours to induce activation of p53
ER. Cells were crosslinked using
formaldehyde, sonicated to shear chromatin, and immunoprecipitated with p53 antibody. A portion of each sample was subject to reverse
crosslinking followed by PCR amplification targeting a region of the p21 promoter, while another portion was used for western blotting to assess the
p53-Mdm2 interaction. B) p21/CDKN1A promoter was PCR amplified and resolved in 1% agarose gel following immunoprecipitation with p53
antibody and reverse crosslinking as shown in (A). C) Western blot following immunoprecipitation with p53 antibody as shown in (A). Membrane was
blotted for Mdm2, stripped, and re-blotted for p53. Note that a band representing Mdm2 is present in the sample immunoprecipitated with p53
antibody but not in p53-null cells, and not following immunoprecipitation with IgG.
doi:10.1371/journal.pone.0038212.g002
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RNA was extracted using the RNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. cDNA was synthe-
sized using SuperScript III (Invitrogen). Quantitative real-time
PCR was performed with SYBR Green using the Applied
Biosystems 7900HT Fast Real-Time PCR System, and data was
collected and exported with SDS 2.2.2. Relative expression was
calculated using GAPDH as an internal control.
Cell Culture
MEF cells were cultured in a 37uC incubator with 5% CO2 in
DMEM supplied with 10% fetal bovine serum (Gibco) and
penicillin (100 IU/ml)/streptomycin (100 mg/ml). To activate
p53
ER, 100 nM 4-hydroxytamoxifen (4-OHT; Sigma) dissolved
in ethanol was added to the culture medium.
Protein Analysis
Cells were lysed in 0.1% NP-40 buffer for immunoprecipitation
and 0.5% NP-40 buffer for straight western blotting. Procedures
and conditions for immunoprecipitation and immunoblotting were
described previously [24]. The following antibodies were pur-
chased commercially: mouse monoclonal Mdm2 (2A-10 and
4B11, Calbiochem), p53 (NCL-505, Novocastra; DO-1, Lab
Vision/Neomarkers), actin (MAB1501, Chemicon International),
goat polyclonal p53 (FL-393; Santa Cruz), and rabbit polyclonal
p53 (CM5, Novocastra). Rabbit polyclonal p21 antibody was a gift
from Dr. Yue Xiong (UNC-Chapel Hill). Rabbit polyclonal
antibodies to L5 and L11 were described previously [25].
Chromatin Immunoprecipitation (ChIP) Analysis
MEF cells were crosslinked using 1% formaldehyde for 10 min
at 37uC and washed with PBS. Crosslinking was stopped with
0.125 M glycine in PBS, cells were washed in PBS, centrifuged for
5 min at 1200 rpm, and pellets were resuspended in Lysis Buffer A
(10 mM Hepes pH 7.5, 0.5% NP40, 1.5 mM MgCl2,1 0m M
KCl, 0.5 mM DTT). Tubes were rotated at 4uC for 30 min and
spun down at 13,000 rpm for 5 min. Proteins not crosslinked to
chromatin were removed, and pellets were resuspended in Lysis
Buffer B (20 mM Hepes pH 7.5, 25% Glycerol, 0.5% NP40, 0.5%
Triton X-100, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
1 mM PMSF, protease inhibitor, and Na3VO4). Lysates were
sonicated for 10 seconds at 1 min intervals a total of 4 times using
a Branson Digital SONIFIERH (Model 250, 450) and Branson
Sound Enclosure (Model SSE-1). Samples were centrifuged for
10 min at 13,000 rpm at 4uC. The supernatant was collected, the
protein concentration was measured, and the supernatant was
mixed with an equal volume of dilution buffer (0.01% SDS, 1.1%
Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8.0, 167 mM
NaCl, 1 mM PMSF, protease inhibitor, and Na3VO4). Samples
were precleared with Protein G Agarose with Salmon Sperm DNA
(Upstate/Millipore, Cat. # 16-201) for 30–60 min at 4uC with
agitation. Samples were spun down at 3000 rpm for 2–5 min at
4uC, and supernatant was collected, with 5% reserved for use as a
loading control for western blotting. Samples were incubated with
antibodies overnight (goat anti-p53 FL393 or goat IgG) using
0.6 mg of antibody per 1 mL sample. 20 mL of Protein G Agarose/
Salmon Sperm DNA was added and samples were incubated for
1 hr, spun at 3000 rpm at 4uC for 3 min, and washed sequentially
with the following buffers at 4uC: TSE I (0.1% SDS, 1% Triton X-
100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl pH 8.0),
TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM
NaCl, 20 mM Tris-HCl pH 8.0), TSE III (0.25 M LiCl, 1%
NP40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl
Figure 3. Immunoprecipitation and western blotting of MEF
cell lysates 24 hours after administration of 4-OHT. Note that
the p53-p300 interaction is enhanced in the Mdm2
m/m MEFs compared
to Mdm2-null MEFs despite similar immunoprecipitation of p53 and
equivalent loading for p300.
doi:10.1371/journal.pone.0038212.g003
Figure 4. Interaction between Mdm2 and Mdmx is impaired in
MEFs with Mdm2
C462A compared to those with wild-type
Mdm2. Immunoprecipitation and western blotting were carried out
24 hours after administering 4-OHT to activate p53
ER. Actin is shown as
a loading control. Note that the interaction between Mdm2 and its
known binding partner L5 is not disrupted by the C462A mutation.
doi:10.1371/journal.pone.0038212.g004
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EDTA). A portion of beads was resuspended in 16sample buffer
for western blotting. For anticrosslinking and PCR, samples were
eluted 36with 75 mL of elution buffer (1%SDS, 0.1M NaHCO3,
1 mM DTT), vortexed briefly, and incubated at room tempera-
ture for 15 min with rotation. Eluates were pooled (200 mL) and
8 mL of 5 M NaCl added. Anticrosslinking was performed at 65uC
for 6 h to overnight. Samples were treated with 4 mL of 0.5 M
EDTA, 4 mL of 2 M Tris-HCl pH 6.8, 2 mL of 10 mg/ml
Proteinase K, 2 mL of 10 mg/ml RNAse A, and incubated for 1 h
at 45 C. DNA was recovered with a QiaQuick PCR Purification
Kit (Qiagen) and eluted with 50 mL of 10 mM Tris-HCl pH 8.5.
PCR was carried out using the following primers for p21
promoter: Promoter mp21 F1 (Forward; CCAGAGGA-
TACCTTGCAAGGC) and Promoter mp21 R1 (Reverse;
TCTCTGTCTCCATTCATGCTCCTCC) [26]. Samples were
resolved on 1% agarose gel.
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